SELLAS Life Sciences Group (SLS) Competitors $1.89 +0.02 (+1.07%) Closing price 04:00 PM EasternExtended Trading$1.87 -0.02 (-1.06%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLS vs. NRIX, DNA, TERN, ANAB, PVLA, MGTX, SIGA, OLMA, KROS, and BCAXShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Nurix Therapeutics (NRIX), Ginkgo Bioworks (DNA), Terns Pharmaceuticals (TERN), AnaptysBio (ANAB), Palvella Therapeutics (PVLA), MeiraGTx (MGTX), Siga Technologies (SIGA), Olema Pharmaceuticals (OLMA), Keros Therapeutics (KROS), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. Its Competitors Nurix Therapeutics Ginkgo Bioworks Terns Pharmaceuticals AnaptysBio Palvella Therapeutics MeiraGTx Siga Technologies Olema Pharmaceuticals Keros Therapeutics Bicara Therapeutics Nurix Therapeutics (NASDAQ:NRIX) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Which has more volatility and risk, NRIX or SLS? Nurix Therapeutics has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.62, suggesting that its stock price is 162% more volatile than the S&P 500. Which has higher valuation & earnings, NRIX or SLS? SELLAS Life Sciences Group has lower revenue, but higher earnings than Nurix Therapeutics. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M13.94-$193.57M-$2.61-3.81SELLAS Life Sciences Group$1M199.02-$30.88M-$0.32-5.91 Does the media refer more to NRIX or SLS? In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 3 mentions for SELLAS Life Sciences Group and 2 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.74 beat SELLAS Life Sciences Group's score of 0.66 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate NRIX or SLS? Nurix Therapeutics presently has a consensus price target of $29.07, suggesting a potential upside of 192.18%. SELLAS Life Sciences Group has a consensus price target of $7.00, suggesting a potential upside of 270.37%. Given SELLAS Life Sciences Group's higher possible upside, analysts plainly believe SELLAS Life Sciences Group is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 1 Sell rating(s) 3 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.76SELLAS Life Sciences Group 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals have more ownership in NRIX or SLS? 17.4% of SELLAS Life Sciences Group shares are held by institutional investors. 7.4% of Nurix Therapeutics shares are held by company insiders. Comparatively, 1.2% of SELLAS Life Sciences Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is NRIX or SLS more profitable? SELLAS Life Sciences Group has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -234.57%. Nurix Therapeutics' return on equity of -45.26% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-234.57% -45.26% -34.71% SELLAS Life Sciences Group N/A -132.51%-92.79% SummaryNurix Therapeutics beats SELLAS Life Sciences Group on 9 of the 17 factors compared between the two stocks. Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$196.91M$3.36B$6.16B$10.57BDividend YieldN/A2.28%5.50%4.66%P/E Ratio-5.9122.0285.5827.12Price / Sales199.02464.24612.74135.85Price / CashN/A46.3226.3031.10Price / Book14.549.9612.876.67Net Income-$30.88M-$52.42M$3.30B$276.23M7 Day Performance21.15%5.95%4.80%3.31%1 Month Performance-1.05%11.59%8.11%10.76%1 Year Performance50.00%25.01%75.85%33.58% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group2.2428 of 5 stars$1.89+1.1%$7.00+270.4%+48.4%$196.91M$1M-5.9110Positive NewsShort Interest ↓NRIXNurix Therapeutics2.1035 of 5 stars$9.28+3.9%$29.07+213.3%-57.7%$682.69M$54.55M-3.56300Positive NewsUpcoming EarningsDNAGinkgo Bioworks1.5705 of 5 stars$13.20+14.8%$9.00-31.8%+93.7%$680.80M$227.04M-2.25640TERNTerns Pharmaceuticals3.8634 of 5 stars$7.79+2.0%$15.49+98.8%-0.5%$668.58MN/A-7.4940Gap UpANABAnaptysBio2.5634 of 5 stars$23.27-1.3%$46.13+98.2%-8.9%$660.17M$91.28M-5.19100Analyst RevisionPVLAPalvella Therapeutics2.2323 of 5 stars$62.25+4.5%$67.09+7.8%N/A$659.04M$42.81M-5.14N/AMGTXMeiraGTx3.9313 of 5 stars$8.25+0.9%$24.00+190.9%+103.6%$658.06M$33.28M-4.04300Positive NewsGap UpSIGASiga Technologies2.0849 of 5 stars$8.96-2.2%N/A+28.2%$655.91M$138.72M7.9340News CoveragePositive NewsOLMAOlema Pharmaceuticals2.8899 of 5 stars$9.54+0.3%$24.00+151.6%-4.3%$652.71MN/A-4.8270KROSKeros Therapeutics2.1225 of 5 stars$15.95-0.6%$30.00+88.1%-73.8%$651.88M$3.55M51.45100BCAXBicara Therapeutics2.4071 of 5 stars$13.87+18.4%$32.25+132.5%-32.3%$638.93MN/A-4.3832Gap UpHigh Trading Volume Related Companies and Tools Related Companies Nurix Therapeutics Alternatives Ginkgo Bioworks Alternatives Terns Pharmaceuticals Alternatives AnaptysBio Alternatives Palvella Therapeutics Alternatives MeiraGTx Alternatives Siga Technologies Alternatives Olema Pharmaceuticals Alternatives Keros Therapeutics Alternatives Bicara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLS) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
